OS Therapies issued a regulatory update on its plans for filing marketing authorizations in the United States and United Kingdom for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.
The company has updated its regulatory filing sequence to prioritize the UK Medicines and Healthcare products Regulatory Agency conditional Marketing Authorisation Application final module submission to immediately precede its US FDA Biologics Licensing Application final module submission under the Accelerated Approval Program. The company expects to complete the MHRA conditional MAA submission in December 2025, with the FDA BLA Accelerated Approval submission expected in January 2025. At the direction of FDA, the company has requested an additional Type C meeting to review updated overall survival and new biomarker data.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.